Skeletal Changes After Hematopoietic Stem Cell Transplantation in Osteopetrosis.
BIOCHEMICAL MARKERS OF BONE TURNOVER
CLINICAL TRIALS
OSTEOCLASTS
OSTEOPETROSIS
RADIOLOGY
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
15
10
2019
revised:
30
03
2020
accepted:
16
04
2020
pubmed:
25
4
2020
medline:
7
7
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
Osteopetrosis is a rare skeletal dysplasia resulting from an osteoclast defect leading to increased bone mass and density. Hematopoietic stem cell transplantation can rescue the disease phenotype and prevent complications. However, little is known about the skeletal changes hematopoietic stem cell transplantation induces in patients with this disease. The purpose of this study was to describe the skeletal changes after hematopoietic stem cell transplantation in a retrospective cohort of patients diagnosed with osteopetrosis in one medical center over 13 years. For this purpose, all available epidemiological, hematological, biochemical, and radiographic data were collected and quantitatively analyzed. We found a significant early change in bone metabolism markers coinciding with hematopoietic recovery after stem cell transplantation. Hematopoietic stem cell transplantation induced a later significant improvement in both skeletal mineral distribution and morphology but did not lead to complete radiological normalization. Presumably, changes in bone metabolism, skeletal mineral distribution, and morphology were the result of renewed osteoclast function enabling bone remodeling. We propose that biochemical bone metabolism markers and radiological indices be routinely used to evaluate response to hematopoietic stem cell transplantation in patients with osteopetrosis. © 2020 American Society for Bone and Mineral Research.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1645-1651Informations de copyright
© 2020 American Society for Bone and Mineral Research.
Références
Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351(27):2839-49.
Villa A, Guerrini MM, Cassani B, Pangrazio A, Sobacchi C. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int. 2009;84(1):1-12.
Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-36.
Gerritsen EJA, Vossen JM, Vanloo IHG, et al. Autosomal recessive osteopetrosis-variability of findings at diagnosis and during the natural course. Pediatrics. 1994;93(2):247-53.
Dlouhy BJ, Menezes AH. Osteopetrosis with Chiari I malformation: presentation and surgical management. J Neurosurg Pediatr. 2011;7(4):369-74.
Steward CG. Neurological aspects of osteopetrosis. Neuropathol Appl Neurobiol. 2003;29(2):87-97.
Landa J, Margolis N, Di Cesare P. Orthopaedic management of the patient with osteopetrosis. J Am Acad Orthop Sur. 2007;15(11):654-62.
Ihde LL, Forrester DM, Gottsegen CJ, et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 2011;31(7):1865-82.
Simanovsky N, Rozovsky K, Hiller N, Weintraub M, Stepensky P. Extending the spectrum of radiological findings in patients with severe osteopetrosis and different genetic backgrounds. Pediatr Blood Cancer. 2016;63(7):1222-6.
Gonen KA, Yazici Z, Gokalp G, Ucar AK. Infantile osteopetrosis with superimposed rickets. Pediatr Radiol. 2013;43(2):189-95.
Schinke T, Schilling AF, Baranowsky A, et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med. 2009;15(6):674-81.
Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4(1):5.
Wu CC, Econs MJ, DiMeglio LA, et al. Diagnosis and management of osteopetrosis: consensus guidelines from the osteopetrosis working group. J Clin Endocrinol Metab. 2017;102(9):3111-23.
Orchard PJ, Fasth AL, Le Rademacher J, et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015;126(2):270-6.
Natsheh J, Drozdinsky G, Simanovsky N, et al. Improved outcomes of hematopoietic stem cell transplantation in patients with infantile malignant osteopetrosis using fludarabine-based conditioning. Pediatr Blood Cancer. 2016;63(3):535-40.
Martinez C, Polgreen L, Defor T, et al. Characterization and management of hypercalcemia following transplantation for osteopetrosis. Bone Marrow Transplant. 2010;45(5):939-44.
Shroff R, Beringer O, Rao K, Hofbauer L, Schulz A. Denosumab for post-transplantation hypercalcemia in osteopetrosis. N Engl J Med. 2012;367(18):1766-7.
Cheow HK, Steward CG, Grier DJ. Imaging of malignant infantile osteopetrosis before and after bone marrow transplantation. Pediatr Radiol. 2001;31(12):869-75.
Costelloe CM, Eftekhari F, Petropoulos D. Radiography of successful bone marrow transplantation for osteopetrosis. Skeletal Radiol. 2007;36(Suppl 1):S34-7.
Hashemi Taheri AP, Radmard AR, Kooraki S, et al. Radiologic resolution of malignant infantile osteopetrosis skeletal changes following hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015;62(9):1645-9.
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-5.
Shadur B, Zaidman I, NaserEddin A, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. Pediatr Blood Cancer. 2018;65(6):e27010.
Friedman LS. Approach to the patient with abnormal liver biochemical and function tests. In Chopra S, ed ; Last updated March 4, 2020. UpToDate [Internet].
FDA. Product information ZYLOPRIM ® (allopurinol).
Faria L, Resende C, Couto C, Couto O, Fonseca L, Ferrari T. Severe and prolonged cholestasis caused by trimethoprim-sulfamethoxazole: a CASE report. Clin Lett. 2009;64(1):71-4.
FDA. Medrol ® methylprednisolone.
Greenblatt M, Tsai J, Wein M. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem. 2017;63(2):464-74.
Nour M, Ward LM. Infantile malignant osteopetrosis. J Pediatr. 2013;163(4):1230-e1.